A comprehensive analysis of SOX17 expression by immunohistochemistry in human epithelial tumors, with an emphasis on gynecologic tumors.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-09-06 DOI:10.1093/ajcp/aqae104

Beth Z Clark, T Rinda Soong, Kanika Goel, Esther Elishaev, Chengquan Zhao, Terri E Jones, Mirka W Jones, Lauren B Skvarca, Samaneh A Motanagh, Gloria J Carter, Jeffrey L Fine, Lakshmi Harinath, Tatiana M Villatoro, Jing Yu, Rohit Bhargava

{"title":"A comprehensive analysis of SOX17 expression by immunohistochemistry in human epithelial tumors, with an emphasis on gynecologic tumors.","authors":"Beth Z Clark, T Rinda Soong, Kanika Goel, Esther Elishaev, Chengquan Zhao, Terri E Jones, Mirka W Jones, Lauren B Skvarca, Samaneh A Motanagh, Gloria J Carter, Jeffrey L Fine, Lakshmi Harinath, Tatiana M Villatoro, Jing Yu, Rohit Bhargava","doi":"10.1093/ajcp/aqae104","DOIUrl":null,"url":null,"abstract":"Objectives: The objective of this study was to evaluate SOX17, a transcription factor from the Sry high-mobility group-related box superfamily, as a diagnostic marker to determine site of origin using both whole-tissue sections and tissue microarrays (TMAs).Methods: SOX17 immunohistochemistry was performed on gynecologic and nongynecologic tissues (N = 1004) using whole-tissue sections and both internally constructed and commercially available TMAs. SOX17 nuclear reactivity was scored as positive or negative on the whole-tissue sections and using the semiquantitative H score method on TMAs.Results: Using both whole-tissue sections and TMAs, SOX17 was positive in 94% (n = 155) of endometrial tumors and 96% (n = 242) of ovarian tumors. All breast cases (n = 241) and vulvar/cervical squamous cell carcinomas (n = 150) were negative. Among 1004 tumors from 20 sites, the only organs with positive tumors were ovary, uterus, and testis.Conclusions: SOX17 is a sensitive and specific marker for gynecologic origin in the tissues tested and may be a valuable adjunct to PAX8 and other commonly used markers to confirm endometrial or ovarian origin. SOX17 expression is lower in mucinous tumors, endocervical adenocarcinoma, high-grade neuroendocrine tumors, and undifferentiated/dedifferentiated endometrial carcinoma.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajcp/aqae104","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The objective of this study was to evaluate SOX17, a transcription factor from the Sry high-mobility group-related box superfamily, as a diagnostic marker to determine site of origin using both whole-tissue sections and tissue microarrays (TMAs).

Methods: SOX17 immunohistochemistry was performed on gynecologic and nongynecologic tissues (N = 1004) using whole-tissue sections and both internally constructed and commercially available TMAs. SOX17 nuclear reactivity was scored as positive or negative on the whole-tissue sections and using the semiquantitative H score method on TMAs.

Results: Using both whole-tissue sections and TMAs, SOX17 was positive in 94% (n = 155) of endometrial tumors and 96% (n = 242) of ovarian tumors. All breast cases (n = 241) and vulvar/cervical squamous cell carcinomas (n = 150) were negative. Among 1004 tumors from 20 sites, the only organs with positive tumors were ovary, uterus, and testis.

Conclusions: SOX17 is a sensitive and specific marker for gynecologic origin in the tissues tested and may be a valuable adjunct to PAX8 and other commonly used markers to confirm endometrial or ovarian origin. SOX17 expression is lower in mucinous tumors, endocervical adenocarcinoma, high-grade neuroendocrine tumors, and undifferentiated/dedifferentiated endometrial carcinoma.

查看原文本刊更多论文

通过免疫组织化学方法全面分析人类上皮肿瘤（重点是妇科肿瘤）中 SOX17 的表达。

研究目的本研究的目的是评估SOX17（Sry高迁移率基团相关盒超家族的一种转录因子）作为诊断标记物的作用，以使用全组织切片和组织芯片（TMA）确定罹患部位：方法：使用全组织切片以及内部构建的和市售的 TMAs 对妇科和非妇科组织（N = 1004）进行 SOX17 免疫组化。全组织切片上的 SOX17 核反应性分为阳性和阴性，TMA 上的 SOX17 核反应性则采用半定量 H 评分法进行评分：使用全组织切片和TMA，94%的子宫内膜肿瘤（n = 155）和96%的卵巢肿瘤（n = 242）SOX17呈阳性。所有乳腺癌病例（n = 241）和外阴/宫颈鳞状细胞癌（n = 150）均为阴性。在来自 20 个部位的 1004 例肿瘤中，只有卵巢、子宫和睾丸的肿瘤呈阳性：结论：在测试的组织中，SOX17是妇科来源的敏感而特异的标记物，可作为PAX8和其他常用标记物的重要辅助工具，用于确认子宫内膜或卵巢来源。SOX17在粘液性肿瘤、宫颈内膜腺癌、高级别神经内分泌肿瘤和未分化/已分化子宫内膜癌中的表达较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464